Jędrysik Malwina, Wyszomirski Krzysztof, Różańska-Walędziak Anna, Grosicka-Maciąg Emilia, Walędziak Maciej, Chełstowska Beata
Department of Biochemistry and Laboratory Diagnostics, Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszynski University in Warsaw, 01-938 Warsaw, Poland.
Department of Human Physiology and Pathophysiology, Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszynski University in Warsaw, 01-938 Warsaw, Poland.
Biomedicines. 2024 Jan 11;12(1):159. doi: 10.3390/biomedicines12010159.
Metabolic illnesses, including obesity and type 2 diabetes, have become worldwide epidemics that have an effect on public health. Clinical investigations and further exploration of these mechanisms could lead to innovative, effective, and personalized treatment strategies for individuals. It is important to screen biomarkers in previous studies to discover what is missing. Glucagon-like peptide-1's role in insulin secretion and glucose control highlights its diagnostic and therapeutic potential. Glucose-dependent insulinotropic peptide's influence on postprandial satiety and weight management signifies its importance in understanding metabolic processes. Monocyte chemoattractant protein-1's involvement in inflammation and insulin resistance underlines its value as a diagnostic marker. Insulin-like growth factor-binding protein-7's association with insulin sensitivity and kidney function presents it as a potential target for these diseases' management. In validating these biomarkers, it will be easier to reflect pathophysiological processes, and clinicians will be able to better assess disease severity, monitor disease progression, and tailor treatment strategies. The purpose of the study was to elucidate the significance of identifying novel biomarkers for type 2 diabetes mellitus and obesity, which can revolutionize early detection, risk assessment, and personalized treatment strategies. Standard literature searches of PubMed (MEDLINE), EMBASE, and Cochrane Library were conducted in the year 2023 to identify both original RCTs and recent systematic reviews that have explored the importance of identifying novel biomarkers for T2D and obesity. This search produced 1964 results, and then was reduced to randomized controlled trial and systematic reviews, producing 145 results and 44 results, respectively. Researchers have discovered potential associations between type 2 diabetes mellitus and obesity and the biomarkers glucagon-like peptide-1, glucose-dependent insulinotropic peptide, monocyte chemoattractant protein-1, and insulin-like growth factor-binding protein-7. Understanding the role of those biomarkers in disease pathogenesis offers hope for improving diagnostics, personalized treatment, and prevention strategies.
包括肥胖症和2型糖尿病在内的代谢性疾病已成为影响公众健康的全球性流行病。对这些机制进行临床研究和进一步探索，可能会为个体带来创新、有效且个性化的治疗策略。在以往研究中筛选生物标志物以发现遗漏之处非常重要。胰高血糖素样肽-1在胰岛素分泌和血糖控制中的作用凸显了其诊断和治疗潜力。葡萄糖依赖性促胰岛素多肽对餐后饱腹感和体重管理的影响表明其在理解代谢过程中的重要性。单核细胞趋化蛋白-1参与炎症和胰岛素抵抗，突显了其作为诊断标志物的价值。胰岛素样生长因子结合蛋白-7与胰岛素敏感性和肾功能的关联使其成为这些疾病管理的潜在靶点。在验证这些生物标志物时，将更容易反映病理生理过程，临床医生将能够更好地评估疾病严重程度、监测疾病进展并制定个性化治疗策略。本研究的目的是阐明识别2型糖尿病和肥胖症新生物标志物的意义，这可能会彻底改变早期检测、风险评估和个性化治疗策略。2023年对PubMed（MEDLINE）、EMBASE和Cochrane图书馆进行了标准文献检索，以识别探索识别2型糖尿病和肥胖症新生物标志物重要性的原始随机对照试验和近期系统评价。该检索产生了1964条结果，然后筛选为随机对照试验和系统评价，分别产生了145条结果和44条结果。研究人员发现2型糖尿病和肥胖症与生物标志物胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽、单核细胞趋化蛋白-1和胰岛素样生长因子结合蛋白-7之间存在潜在关联。了解这些生物标志物在疾病发病机制中的作用为改善诊断、个性化治疗和预防策略带来了希望。
